Bibliography

1. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group. Eur Heart J 1988;9(1):8-16.
2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2(8607):349-60.
3. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group. Jama 1988;259(14):2113-22.
4. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992;339(8796):753-70.
5. Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Eur Heart J 1992;13(5):594-8.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
7. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343(8906):1115-22.
8. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343(8893):311-22.
9. Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. Bmj 1994;308(6923):235-46.
10. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308(6921):81-106.
11. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345(8951):669-85.
12. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. Lancet 1995;346(8984):1179-84.
13. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. J Am Coll Cardiol 1996;27(2):337-44.
14. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348(9038):1329-39.
15. North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management angina. North of England Stable Angina Guideline Development Group. Bmj 1996;312(7034):827-32.
16. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997;350(9076):461-8.
17. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. J Hypertens 1998;16(2):127-37.
18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339(19):1349-57.
19. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998;97(22):2202-12.

20. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998;316(7135):894-8.
21. Collaborative overview ('meta-analysis') of prospective observational studies of the associations of usual blood pressure and usual cholesterol levels with common causes of death: protocol for the second cycle of the Prospective Studies Collaboration. J Cardiovasc Risk 1999;6(5):315-20.
22. Prediction of risk for patients with unstable angina. Evid Rep Technol Assess (Summ) 2000(31):1-3.
23. Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists' Collaborative Group. Am Heart J 2001;141(1):E2.
24. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
25. Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988;260(23):3456-60.
26. Abbott RD, Wilson PW, Kannel WB, et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis 1988;8(3):207-11.
27. Ades PA, Savage PD, Poehlman ET, et al. Lipid lowering in the cardiac rehabilitation setting. J Cardiopulm Rehabil 1999;19(4):255-60.
28. Afonso LC, Edelson GW, Sowers JR. Metabolic abnormalities in hypertension. Curr Opin Nephrol Hypertens 1997;6(3):219-23.
29. Airaksinen KE. Autonomic mechanisms and sudden death after abrupt coronary occlusion. Ann Med 1999;31(4):240-5.
30. Al Suwaidi J, Berger PB, Holmes DR, Jr. Coronary artery stents. Jama 2000;284(14):1828-36.
31. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Jama 2001;286(1):64-70.
32. Alderman MH, Ooi WL, Madhavan S, et al. Treatment-induced blood pressure reduction and the risk of myocardial infarction. Jama 1989;262(7):920-4.
33. Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998;32(6):1657-64.
34. Allison JJ, Kiefe CI, Centor RM, et al. Racial differences in the medical treatment of elderly Medicare patients with acute myocardial infarction. J Gen Intern Med 1996;11(12):736-43.
35. Amanullah AM, Kiat H, Friedman JD, et al. Adenosine technetium-99m sestamibi myocardial perfusion SPECT in women: diagnostic efficacy in detection of coronary artery disease. J Am Coll Cardiol 1996;27(4):803-9.
36. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. Jama 1999;282(21):2058-67.
37. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. Jama 1987;257(16):2176-80.
38. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. Jama 1999;282(21):2051-7.
39. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100(15):1602-8.
40. Aronow WS. Management of older persons after myocardial infarction. J Am Geriatr Soc 1998;46(11):1459-68.
41. Arruda-Olson AM, Juracan EM, Mahoney DW, et al. Prognostic value of exercise echocardiography in 5,798 patients: is there a gender difference? J Am Coll Cardiol 2002;39(4):625-31.
42. Ascherio A, Willett WC. Health effects of trans fatty acids. Am J Clin Nutr 1997;66(4 Suppl):1006S-1010S.
43. Atrens DM. The questionable wisdom of a low-fat diet and cholesterol reduction. Soc Sci Med 1994;39(3):433-47.
44. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol 1998;14(Suppl B):14B-17B.
45. Austin MA. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 1999;83(9B):13F-16F.

46. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(4A):7B-12B.
47. Avezum A, Tsuyuki RT, Pogue J, et al. Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials. Can J Cardiol 1998;14(8):1045-53.
48. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991;325(4):221-5.
49. Azar RR, Waters DD, McKay RG, et al. Short- and medium-term outcome differences in women and men after primary percutaneous transluminal mechanical revascularization for acute myocardial infarction. Am J Cardiol 2000;85(6):675-9.
50. Baevsky RM, Petrov VM, Cornelissen G, et al. Meta-analyzed heart rate variability, exposure to geomagnetic storms, and the risk of ischemic heart disease. Scr Med (Brno) 1997;70(4-5):201-6.
51. Balk EM, Ioannidis JP, Salem D, et al. Accuracy of biomarkers to diagnose acute cardiac ischemia in the emergency department: a meta-analysis. Ann Emerg Med 2001;37(5):478-94.
52. Bandyopadhyay S, Bayer AJ, O'Mahony MS. Age and gender bias in statin trials. Qjm 2001;94(3):127-32.
53. Barbour MM, Hume AL, Lapane KL, et al. Predictors of future antihypertensive use in patients with mildly elevated blood pressure. Pharmacotherapy 1995;15(3):272-8.
54. Barnes V, Schneider R, Alexander C, et al. Stress, stress reduction, and hypertension in African Americans: an updated review. J Natl Med Assoc 1997;89(7):464-76.
55. Barratt A, Irwig L. Is cholesterol testing/treatment really beneficial? Med J Aust 1993;159(10):644-7.
56. Barrett-Connor EL. Obesity, atherosclerosis, and coronary artery disease. Ann Intern Med 1985;103(6 (Pt 2)):1010-9.
57. Basinski A, Naylor CD. Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy. J Clin Epidemiol 1991;44(10):1085-96.
58. Batchelor WB, Anstrom KJ, Muhlbaier LH, et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. J Am Coll Cardiol 2000;36(3):723-30.
59. Bates DW, Miller E, Bernstein SJ, et al. Coronary angiography and angioplasty after acute myocardial infarction. Ann Intern Med 1997;126(7):539-50.
60. Battleman DS, Callahan M. Gender differences in utilization of exercise treadmill testing: a claims-based analysis. J Healthc Qual 2001;23(3):38-41.
61. Bax JJ, Wijns W, Cornel JH, et al. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997;30(6):1451-60.
62. Beck CA, Lauzon C, Eisenberg MJ, et al. Discharge prescriptions following admission for acute myocardial infarction at tertiary care and community hospitals in Quebec. Can J Cardiol 2001;17(1):33-40.
63. Becker RC. Late thrombolytic therapy: mechanism of benefit and potential risk among patients treated beyond 6 hours. Coron Artery Dis 1993;4(3):293-304.
64. Becker RC, Terrin M, Ross R, et al. Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. Ann Intern Med 1994;120(8):638-45.
65. Beckett N, Nunes M, Bulpitt C. Is it advantageous to lower cholesterol in the elderly hypertensive? Cardiovasc Drugs Ther 2000;14(4):397-405.
66. Beckwith C, Munger MA. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother 1993;27(6):755-66.
67. Bell DM. Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes. Pharmacotherapy 1999;19(9):1086-93.
68. Bell MR, Grill DE, Garratt KN, et al. Long-term outcome of women compared with men after successful coronary angioplasty. Circulation 1995;91(12):2876-81.
69. Bell MR, Holmes DR, Jr., Berger PB, et al. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty. JAMA 1993;269(16):2091-5.
70. Bergelson BA, Tommaso CL. Gender differences in clinical evaluation and triage in coronary artery disease. Chest 1995;108(6):1510-3.
71. Bergelson BA, Tommaso CL. Gender differences in percutaneous interventional therapy of coronary artery disease. Cathet Cardiovasc Diagn 1996;37(1):1-4.

72. Bergfeldt L. HLA-B27-associated cardiac disease. Ann Intern Med 1997;127(8 Pt 1):621-9.
73. Bergman U, Anderssen M, Vaccheri A, et al. Marked differences in lipid-lowering drug use in Bologna, Italy and Funen, Denmark. Eur Heart J 1999;20(15):1135.
74. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990;132(4):612-28.
75. Bernstein SJ, Hilborne LH, Leape LL, et al. The appropriateness of use of cardiovascular procedures in women and men. Arch Intern Med 1994;154(23):2759-65.
76. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Jama 2000;284(12):1549-58.
77. Bhopal R. What is the risk of coronary heart disease in South Asians? A review of UK research. J Public Health Med 2000;22(3):375-85.
78. Bickell NA, Pieper KS, Lee KL, et al. Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? Ann Intern Med 1992;116(10):791-7.
79. Bijsterveld NR, Hettiarachchi R, Peters R, et al. Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost 1999;82(Suppl 1):139-47.
80. Bizjak ED, Mauro VF. Thrombolytic therapy: a review of its use in acute myocardial infarction. Ann Pharmacother 1998;32(7-8):769-84.
81. Bjorntorp P. Evolution of the understanding of the role of exercise in obesity and its complications. Int J Obes Relat Metab Disord 1995;19(Suppl 4):S1-4.
82. Blair SN, Brodney S. Effects of physical inactivity and obesity on morbidity and mortality: current evidence and research issues. Med Sci Sports Exerc 1999;31(11 Suppl):S646-62.
83. Blair SN, Kohl HW, 3rd, Paffenbarger RS, Jr., et al. Physical fitness and all-cause mortality. A prospective study of healthy men and women. Jama 1989;262(17):2395-401.
84. Blankenhorn DH, Hodis HN. Atherosclerosis--reversal with therapy. West J Med 1993;159(2):172-9.
85. Blazing MA, O'Connor CM. Evidence supporting secondary prevention strategies. Curr Opin Cardiol 1999;14(4):303-9.
86. Blustein J, Weitzman BC. Access to hospitals with high-technology cardiac services: how is race important? Am J Public Health 1995;85(3):345-51.
87. Boden WE, Vray M, Eschwege E, et al. Heart rate-lowering and -regulating effects of once-daily sustained-release diltiazem. Clin Cardiol 2001;24(1):73-9.
88. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999;100(20):2045-8.
89. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359(9302):189-98.
90. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348(9030):771-5.
91. Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1989;62(2):681-5.
92. Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000;160(5):621-7.
93. Borgia MC, Medici F. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. Angiology 1998;49(5):339-48.
94. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med 1995;123(11):873-7.
95. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159(10):1077-80.
96. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274(13):1049-57.

97. Bradley KA, Badrinath S, Bush K, et al. Medical risks for women who drink alcohol. J Gen Intern Med 1998;13(9):627-39.
98. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes 1989;38(4):504-9.
99. Brand FN, Kiely DK, Kannel WB, et al. Family patterns of coronary heart disease mortality: the Framingham Longevity Study. J Clin Epidemiol 1992;45(2):169-74.
100. Braunwald E, Maseri A, Armstrong PW, et al. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J 1998;19(Suppl D):D22-30.
101. Brezinka V, Kittel F. Psychosocial factors of coronary heart disease in women: a review. Soc Sci Med 1996;42(10):1351-65.
102. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134(7):550-60.
103. Brown BG, Zhao XQ, Chait A, et al. Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design. Can J Cardiol 1998;14(Suppl A):6A-13A.
104. Brown DL, Fann CS, Chang CJ. Effect of glycoprotein IIb/IIIa inhibitors on the individual components of composite endpoints used in clinical trials of unstable angina and non-Q-wave myocardial infarction. Cardiovasc Drugs Ther 2000;14(3):253-8.
105. Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87(5):537-41.
106. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999;19(2):187-95.
107. Buchwald H, Campos CT, Boen JR, et al. Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials. Ann Surg 1996;224(4):486-98; discussion 498-500.
108. Budoff MJ, Diamond GA, Raggi P, et al. Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography. Circulation 2002;105(15):1791-6.
109. Budoff MJ, Shokooh S, Shavelle RM, et al. Electron beam tomography and angiography: sex differences. Am Heart J 2002;143(5):877-82.
110. Burke AP, Farb A, Malcom GT, et al. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998;97(21):2110-6.
111. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem 1988;34(8B):B60-70.
112. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92(9):2419-25.
113. Califf RM, Harrell FE, Jr., Lee KL, et al. The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. Jama 1989;261(14):2077-86.
114. Cantor WJ, Peterson ED, Popma JJ, et al. Provisional stenting strategies: systematic overview and implications for clinical decision-making. J Am Coll Cardiol 2000;36(4):1142-51.
115. Capewell S, MacIntyre K, Stewart S, et al. Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study. Lancet 2001;358(9289):1213-7.
116. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999;81(4):380-6.
117. Carlisle DM, Leake BD, Shapiro MF. Racial and ethnic differences in the use of invasive cardiac procedures among cardiac patients in Los Angeles County, 1986 through 1988. Am J Public Health 1995;85(3):352-6.
118. Carlisle DM, Leake BD, Shapiro MF. Racial and ethnic disparities in the use of cardiovascular procedures: associations with type of health insurance. Am J Public Health 1997;87(2):263-7.
119. Carter BL, Kriesel HT, Steinkraus L, et al. Antihypertensive drug-prescribing patterns of internists and family physicians. J Fam Pract 1989;29(3):257-61.
120. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol 1988;4(Suppl A):5A-10A.
121. Castelli WP. Diet, smoking, and alcohol: influence on coronary heart disease risk. Am J Kidney Dis 1990;16(4 Suppl 1):41-6.

122. Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2(1-2):23-8.
123. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. Jama 1986;256(20):2835-8.
124. Castelli WP, Wilson PW, Levy D, et al. Cardiovascular risk factors in the elderly. Am J Cardiol 1989;63(16):12H-19H.
125. Castillo PA, Palmer CS, Halpern MT, et al. Cost-effectiveness of thrombolytic therapy for acute myocardial infarction. Ann Pharmacother 1997;31(5):596-603.
126. Celis H, Fagard R, Staessen J, et al. The older hypertensive. Assessment and treatment. Neth J Med 1993;43(Suppl 1):S66-77.
127. Cerqueira MD. Diagnostic testing strategies for coronary artery disease: special issues related to gender. Am J Cardiol 1995;75(11):52D-60D.
128. Chaitman BR, Bourassa MG, Davis K, et al. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). Circulation 1981;64(2):360-7.
129. Chandra NC, Ziegelstein RC, Rogers WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch Intern Med 1998;158(9):981-8.
130. Chew DP, Bhatt DL, Sapp S, et al. Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists : A Meta-Analysis of Phase III Multicenter Randomized Trials. Circulation 2001;103(2):201-206.
131. Chiamvimonvat V, Sternberg L. Coronary artery disease in women. Can Fam Physician 1998;44:2709-17.
132. Chiriboga DE, Yarzebski J, Goldberg RJ, et al. A community-wide perspective of gender differences and temporal trends in the use of diagnostic and revascularization procedures for acute myocardial infarction. Am J Cardiol 1993;71(4):268-73.
133. Cho L, Bhatt DL, Wolski K, et al. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT. Am Heart J 2001;141(4):599-602.
134. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000;36(2):381-6.
135. Christenson RH, Duh SH. Evidence based approach to practice guides and decision thresholds for cardiac markers. Scand J Clin Lab Invest Suppl 1999;230:90-102.
136. Clarke KW, Gray D, Keating NA, et al. Do women with acute myocardial infarction receive the same treatment as men? Bmj 1994;309(6954):563-6.
137. Clarkson TB, Kaplan JR, Adams MR, et al. Psychosocial influences on the pathogenesis of atherosclerosis among nonhuman primates. Circulation 1987;76(1 Pt 2):I29-40.
138. Cleland JG, Bristow MR, Erdmann E, et al. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J 1996;17(11):1629-39.
139. Cleophas TJ, Hornstra N, van Hoogstraten B, et al. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. Am J Cardiol 2000;86(9):1005-9, A8.
140. Clyne CA. Antithrombotic therapy in the primary and secondary prevention of coronary-related death and infarction: focus on gender differences. Cardiology 1990;77(Suppl 2):99-109.
141. Cohen M. The role of low-molecular-weight heparins in arterial diseases: optimizing antithrombotic therapy. Thromb Res 2000;100(2):V131-9.
142. Colditz GA, Halvorsen KT, Goldhaber SZ. Randomized clinical trials of transdermal nitroglycerin systems for the treatment of angina: a meta-analysis. Am Heart J 1988;116(1 Pt 1):174-80.
143. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316(18):1105-10.
144. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Bmj 1996;313(7058):652-9.
145. Collins R, Peto R, Parish S, et al. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. Am J Cardiol 1993;71(12):1127-30.

146. Conlan MG, Folsom AR, Finch A, et al. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993;70(5):762-7.
147. Conti CR. Large vessel coronary vasospasm: diagnosis, natural history and treatment. Am J Cardiol 1985;55(3):41B-49B.
148. Conti CR. Clinical decision making using cumulative meta-analysis. Clin Cardiol 1993;16(3):167-8.
149. Cooke HM, Lynch A. Biorhythms and chronotherapy in cardiovascular disease. Am J Hosp Pharm 1994;51(20):2569-80.
150. Cooper GS, Sandler DP. Age at natural menopause and mortality. Ann Epidemiol 1998;8(4):229-35.
151. Cooper R. The role of genetic and environmental factors in cardiovascular disease in African Americans. Am J Med Sci 1999;317(3):208-13.
152. Cooper RS, Ghali JK. Coronary heart disease: black-white differences. Cardiovasc Clin 1991;21(3):205-25.
153. Corrao G, Rubbiati L, Bagnardi V, et al. Alcohol and coronary heart disease: a meta-analysis. Addiction 2000;95(10):1505-23.
154. Corti MC, Guralnik JM, Bilato C. Coronary heart disease risk factors in older persons. Aging (Milano) 1996;8(2):75-89.
155. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22(2):233-40.
156. Craig WY, Neveux LM, Palomaki GE, et al. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998;44(11):2301-6.
157. Croft JB, Keenan NL, Sheridan DP, et al. Waist-to-hip ratio in a biracial population: measurement, implications, and cautions for using guidelines to define high risk for cardiovascular disease. J Am Diet Assoc 1995;95(1):60-4.
158. Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. Cochrane Database Syst Rev 2000(2):CD001560.
159. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161(11):1413-9.
160. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000;86(9):943-9.
161. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103(15):1967-71.
162. D'Agostino RB, Cobb JL, Wolf PA, et al. Aspirin use and cardiovascular disease in women. Jama 1992;267(3):364-5.
163. D'Agostino RB, Sr., Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. Jama 2001;286(2):180-7.
164. D'Agostino RB, Kannel WB, Belanger AJ, et al. Trends in CHD and risk factors at age 55-64 in the Framingham Study. Int J Epidemiol 1989;18(3 Suppl 1):S67-72.
165. D'Agostino RB, Kannel WB, Stepanians MN, et al. Efficacy and tolerability of lovastatin in hypercholesterolemic women. Clin Ther 1992;14(3):390-5.
166. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139(2 Pt 1):272-81.
167. D'Hoore W, Sicotte C, Tilquin C. Sex bias in the management of coronary artery disease in Quebec. Am J Public Health 1994;84(6):1013-5.
168. Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104(5):522-6.
169. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003.
170. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. Jama 1998;279(18):1477-82.

171. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102(10):1082-5.
172. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996;17(1):104-12.
173. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992;56(2):320-8.
174. Davie AP. ACE inhibitors after myocardial infarction. Clinical and economic considerations. Pharmacoeconomics 2000;17(3):237-43.
175. Davis KB, Chaitman B, Ryan T, et al. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. Coronary Artery Surgery Study. J Am Coll Cardiol 1995;25(5):1000-9.
176. de Albuquerque Fonseca L, Picano E. Comparison of dipyridamole and exercise stress echocardiography for detection of coronary artery disease (a meta-analysis). Am J Cardiol 2001;87(10):1193-6; A4.
177. de Feyter PJ, Keane D, Deckers JW, et al. Medium- and long-term outcome after coronary balloon angioplasty. Prog Cardiovasc Dis 1994;36(5):385-96.
178. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357(9250):89-95.
179. de Jaegere PP, Eefting FD, Popma JJ, et al. Clinical trials on intracoronary stenting. Semin Interv Cardiol 1996;1(4):233-45.
180. Degeare VS, Dangas G, Stone GW, et al. Interventional procedures in acute myocardial infarction. Am Heart J 2001;141(1):15-24.
181. DeGeare VS, Stone GW, Grines L, et al. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am J Cardiol 2000;86(1):30-4.
182. Denollet J. Type D personality. A potential risk factor refined. J Psychosom Res 2000;49(4):255-66.
183. Denvir MA, Martin W, Tweddel AC, et al. A comparison of adenosine and exercise stress 201T1 scintigraphy. Nucl Med Commun 1994;15(6):410-6.
184. Detrano R. Variability in the accuracy of the exercise ST-segment in predicting the coronary angiogram: how good can we be? J Electrocardiol 1992;24(Suppl):54-61.
185. Detrano R, Gianrossi R, Froelicher V. The diagnostic accuracy of the exercise electrocardiogram: a meta-analysis of 22 years of research. Prog Cardiovasc Dis 1989;32(3):173-206.
186. Detrano R, Gianrossi R, Mulvihill D, et al. Exercise-induced ST segment depression in the diagnosis of multivessel coronary disease: a meta analysis. J Am Coll Cardiol 1989;14(6):1501-8.
187. Detrano R, Hsiai T, Wang S, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. J Am Coll Cardiol 1996;27(2):285-90.
188. Detrano R, Janosi A, Lyons KP, et al. Factors affecting sensitivity and specificity of a diagnostic test: the exercise thallium scintigram. Am J Med 1988;84(4):699-710.
189. Detrano R, Lyons KP, Marcondes G, et al. Methodologic problems in exercise testing research. Are we solving them? Arch Intern Med 1988;148(6):1289-95.
190. Detre KM, Rosen AD, Bost JE, et al. Contemporary practice of coronary revascularization in U.S. hospitals and hospitals participating in the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol 1996;28(3):609-15.
191. Di Salvo TT, Paul SD, Lloyd-Jones D, et al. Care of acute myocardial infarction by noninvasive and invasive cardiologists: procedure use, cost and outcome. J Am Coll Cardiol 1996;27(2):262-9.
192. Diaz LA, Brunken RC, Blackstone EH, et al. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. J Am Coll Cardiol 2001;37(6):1558-64.
193. DiBianco R. Bepridil treatment of chronic stable angina: a review of comparative studies versus placebo, nifedipine, and diltiazem. Am J Cardiol 1992;69(11):56D-62D.
194. Dickes MS, Stammers AH, Pierce ML, et al. Outcome analysis of coronary artery bypass grafting: minimally invasive versus standard techniques. Perfusion 1999;14(6):461-72.

195. Dimmitt SB. Recent insights into dietary fats and cardiovascular disease. Clin Exp Pharmacol Physiol 1995;22(3):204-8.
196. Dippel DW. The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial. Thromb Res 1998;92(1 Suppl 1):S13-6.
197. Doherty TM, Detrano RC, Mautner SL, et al. Coronary calcium: the good, the bad, and the uncertain. Am Heart J 1999;137(5):806-14.
198. Doliszny KM, Luepker RV, Burke GL, et al. Estimated contribution of coronary artery bypass graft surgery to the decline in coronary heart disease mortality: the Minnesota Heart Survey. J Am Coll Cardiol 1994;24(1):95-103.
199. Dollery C. Diuretic agents and beta-blockers in the treatment of hypertension. Hypertension 1989;13(5 Suppl):I62-5.
200. Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33(3):598-604.
201. Donahue RP, Goldberg RJ, Chen Z, et al. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol 1993;46(3):245-52.
202. Doran JP, Howie AJ, Townend JN, et al. Detection of myocardial infarction by immunohistological staining for C9 on formalin fixed, paraffin wax embedded sections. J Clin Pathol 1996;49(1):34-7.
203. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997;18(4):560-5.
204. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Jama 1998;279(20):1615-22.
205. Du W, Ash AS, Berlowitz DR, et al. Variations in the management of acute myocardial infarction. Importance of clinical measures of disease severity. J Gen Intern Med 1996;11(6):334-41.
206. Duprez D. Is vascular disease in the female different from men? Int Angiol 1993;12(4):331-4.
207. Dzavik V, Carere RG, Teo KK, et al. An open design, multicentre, randomized trial of percutaneous transluminal coronary angioplasty versus stenting, with a heparin-coated stent, of totally occluded coronary arteries: rationale, trial design and baseline patient characteristics. Total Occlusion Study of Canada (TOSCA) Investigators. Can J Cardiol 1998;14(6):825-32.
208. Eaton CB. Relation of physical activity and cardiovascular fitness to coronary heart disease, Part I: A meta-analysis of the independent relation of physical activity and coronary heart disease. J Am Board Fam Pract 1992;5(1):31-42.
209. Ebell MH, White LL, Weismantel D. A systematic review of troponin T and I values as a prognostic tool for patients with chest pain. J Fam Pract 2000;49(8):746-53.
210. Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. Bmj 1997;314(7095):1666-74.
211. Eckman MH, Wong JB, Salem DN, et al. Direct angioplasty for acute myocardial infarction. A review of outcomes in clinical subsets. Ann Intern Med 1992;117(8):667-76.
212. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355(9219):1936-42.
213. Einbinder LC, Schulman KA. The effect of race on the referral process for invasive cardiac procedures. Med Care Res Rev 2000;57(Suppl 1):162-80.
214. Elliott WJ. Circadian variation in blood pressure: implications for the elderly patient. Am J Hypertens 1999;12(2 Pt 2):43S-49S.
215. Ellis SG, Da Silva ER, Spaulding CM, et al. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. Am Heart J 2000;139(6):1046-53.
216. Ellis SG, Roubin GS, King SB, 3rd, et al. In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 procedures. J Am Coll Cardiol 1988;11(2):211-6.
217. Emery EM, Schmid TL, Kahn HS, et al. A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am J Health Promot 1993;7(5):342-53.

218. Engman ML. An update on EBCT (Ultrafast CT) scans for coronary artery disease. J Insur Med 1998;30(3):175-9.
219. Eysmann SB, Douglas PS. Reperfusion and revascularization strategies for coronary artery disease in women. Jama 1992;268(14):1903-7.
220. Fager G, Wiklund O. Cholesterol reduction and clinical benefit. Are there limits to our expectations? Arterioscler Thromb Vasc Biol 1997;17(12):3527-33.
221. Feit F, Mueller HS, Braunwald E, et al. Thrombolysis in Myocardial Infarction (TIMI) phase II trial: outcome comparison of a "conservative strategy" in community versus tertiary hospitals. The TIMI Research Group. J Am Coll Cardiol 1990;16(7):1529-34.
222. Ferguson TB, Jr., Muhlbaier LH, Salai DL, et al. Coronary bypass grafting after failed elective and failed emergent percutaneous angioplasty. Relative risks of emergent surgical intervention. J Thorac Cardiovasc Surg 1988;95(5):761-72.
223. Fernandes CJ, Jr., Akamine N, Knobel E. Cardiac troponin: a new serum marker of myocardial injury in sepsis. Intensive Care Med 1999;25(10):1165-8.
224. Fiebach NH, Hebert PR, Stampfer MJ, et al. A prospective study of high blood pressure and cardiovascular disease in women. Am J Epidemiol 1989;130(4):646-54.
225. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001;161(13):1581-6.
226. Findlay IN. Coronary bypass surgery in women. Curr Opin Cardiol 1994;9(6):650-7.
227. Fioretti F, Tavani A, Gallus S, et al. Menopause and risk of non-fatal acute myocardial infarction: an Italian case-control study and a review of the literature. Hum Reprod 2000;15(3):599-603.
228. Fiorino AS. Electron-beam computed tomography, coronary artery calcium, and evaluation of patients with coronary artery disease. Ann Intern Med 1998;128(10):839-47.
229. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355(9215):1575-81.
230. Fleischmann KE, Hunink MG, Kuntz KM, et al. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. Jama 1998;280(10):913-20.
231. Flores-Runk P, Raasch RH. Ticlopidine and antiplatelet therapy. Ann Pharmacother 1993;27(9):1090-8.
232. Fodor JG, Boulet AP, Savard D, et al. The role of diltiazem in treating hypertension and coronary artery disease: new approaches to preventing first events. Can J Cardiol 1997;13(5):495-503.
233. Folsom AR. Epidemiology of fibrinogen. Eur Heart J 1995;16(Suppl A):21-3; discussion 23-4.
234. Folsom AR, Arnett DK, Hutchinson RG, et al. Physical activity and incidence of coronary heart disease in middle-aged women and men. Med Sci Sports Exerc 1997;29(7):901-9.
235. Folsom AR, Burke GL, Byers CL, et al. Implications of obesity for cardiovascular disease in blacks: the CARDIA and ARIC studies. Am J Clin Nutr 1991;53(6 Suppl):1604S-1611S.
236. Folsom AR, French SA, Zheng W, et al. Weight variability and mortality: the Iowa Women's Health Study. Int J Obes Relat Metab Disord 1996;20(8):704-9.
237. Folsom AR, Kushi LH, Anderson KE, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. Arch Intern Med 2000;160(14):2117-28.
238. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998;98(3):204-10.
239. Folsom AR, Stevens J, Schreiner PJ, et al. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Atherosclerosis Risk in Communities Study Investigators. Am J Epidemiol 1998;148(12):1187-94.
240. Folsom AR, Szklo M, Stevens J, et al. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1997;20(6):935-42.
241. Ford ES, Cooper RS. Racial/ethnic differences in health care utilization of cardiovascular procedures: a review of the evidence. Health Serv Res 1995;30(1 Pt 2):237-52.
242. Fox KA. Comparative analysis of long-term mortality after thrombolytic therapy. Am J Cardiol 1991;68(16):38E-44E.

243. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. Bmj 1999;318(7200):1730-7.
244. French JK, Webster MW, Neutze JM, et al. Evidence-based assessment of the benefit of revascularisation in coronary disease: beyond the randomised trials. Aust N Z J Med 1996;26(4):490-4.
245. French SA, Folsom AR, Jeffery RW, et al. Weight variability and incident disease in older women: the Iowa Women's Health Study. Int J Obes Relat Metab Disord 1997;21(3):217-23.
246. Freund KM, Belanger AJ, D'Agostino RB, et al. The health risks of smoking. The Framingham Study: 34 years of follow-up. Ann Epidemiol 1993;3(4):417-24.
247. Froom J, Froom P, Benjamin M, et al. Measurement and management of hyperlipidemia for the primary prevention of coronary heart disease. J Am Board Fam Pract 1998;11(1):12-22.
248. Fu Y, Chang WC, Mark D, et al. Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. Circulation 2000;102(12):1375-81.
249. Fuentes R, Ilmaniemi N, Laurikainen E, et al. Hypertension in developing economies: a review of population-based studies carried out from 1980 to 1998. J Hypertens 2000;18(5):521-9.
250. Fuller JH, Stevens LK, Wang SL. International variations in cardiovascular mortality associated with diabetes mellitus: the WHO Multinational Study of Vascular Disease in Diabetes. Ann Med 1996;28(4):319-22.
251. Furberg CD. Lipid-lowering trials: results and limitations. Am Heart J 1994;128(6 Pt 2):1304-8.
252. Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol 2001;37(5):1456-60.
253. Furberg CD, Psaty BM. Corrections to the nifedipine meta-analysis. Circulation 1996;93(7):1475-6.
254. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92(5):1326-31.
255. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Part 2. Ann Intern Med 1996;124(5):518-31.
256. Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med 1999;130(9):719-28.
257. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. Jama 1995;273(18):1450-6.
258. Garrison RJ, Gold RS, Wilson PW, et al. Educational attainment and coronary heart disease risk: the Framingham Offspring Study. Prev Med 1993;22(1):54-64.
259. Garzon PP, Eisenberg MJ. Functional testing for the detection of restenosis after percutaneous transluminal coronary angioplasty: a meta-analysis. Can J Cardiol 2001;17(1):41-8.
260. Gaziano JM, Skerrett PJ, Buring JE. Aspirin in the treatment and prevention of cardiovascular disease. Haemostasis 2000;30(Suppl 3):1-13.
261. Genest J, Jr., Jenner JL, McNamara JR, et al. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 1991;67(13):1039-145.
262. Ghali JK, Pina IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002;105(13):1585-91.
263. Giacomini MK. Gender and ethnic differences in hospital-based procedure utilization in California. Arch Intern Med 1996;156(11):1217-24.
264. Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989;80(1):87-98.
265. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation 1997;96(1):345-54.
266. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997;30(1):260-311.
267. Gibson CM, Moynihan JL, Al-Mousa EN, et al. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology. J Thromb Thrombolysis 1999;7(3):287-302.

268. Gibson RS, Boden WE. Calcium channel antagonists: friend or foe in postinfarction patients? Am J Hypertens 1996;9(12 Pt 2):172S-176S.
269. Giles TD, Fisher MB, Rush JE. Lisinopril and captopril in the treatment of heart failure in older patients. Comparison of a long- and short-acting angiotensin-converting enzyme inhibitor. Am J Med 1988;85(3B):44-7.
270. Gill D, Mayou R, Dawes M, et al. Presentation, management and course of angina and suspected angina in primary care. J Psychosom Res 1999;46(4):349-58.
271. Giugliano RP, Llevadot J, Wilcox RG, et al. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J 2001;22(18):1702-15.
272. Giugliano RP, McCabe CH, Antman EM, et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001;141(5):742-50.
273. Glasser SP, Frishman W, White WB, et al. Circadian heart rate response to chronotherapy versus conventional therapy in patients with hypertension and myocardial ischemia. Clin Cardiol 2000;23(7):524-9.
274. Godsland IF, Wynn V, Crook D, et al. Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J 1987;114(6):1467-503.
275. Goldberg KC, Hartz AJ, Jacobsen SJ, et al. Racial and community factors influencing coronary artery bypass graft surgery rates for all 1986 Medicare patients. Jama 1992;267(11):1473-7.
276. Goldberg L, Elliot DL. The effect of physical activity on lipid and lipoprotein levels. Med Clin North Am 1985;69(1):41-55.
277. Goldman L, Coxson P, Hunink MG, et al. The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines. J Am Coll Cardiol 1999;34(3):768-76.
278. Goldman L, Weinstein MC, Williams LW. Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model. Circulation 1989;80(2):254-60.
279. Gonzalez MA, Rodriguez Artalejo F, Calero JR. Relationship between socioeconomic status and ischaemic heart disease in cohort and case-control studies: 1960-1993. Int J Epidemiol 1998;27(3):350-8.
280. Gotto AM, Jr. Heart disease in the assessment and treatment of hypercholesterolemia: coronary artery disease and other atherosclerotic disease, family history, and left ventricular hypertrophy. Am J Med 1994;96(6A):9S-18S.
281. Gotto AM, Jr., Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation 1999;99(8):E1-7.
282. Gould AL, Cariski AT. Meta-analysis by the Program on the Surgical Control of the Hyperlipidemias (POSCH) investigators. Ann Surg 1998;227(2):314-6.
283. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995;91(8):2274-82.
284. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97(10):946-52.
285. Grady D, Herrington D, Vittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA 2002;288:49-57.
286. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117(12):1016-37.
287. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93(5):870-8.
288. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353(9152):571-80.
289. Greenland P, Reicher-Reiss H, Goldbourt U, et al. In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. Circulation 1991;83(2):484-91.
290. Gregoire JP, Moisan J, Guibert R, et al. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther 2001;23(5):715-26.
291. Gronbaek M. Wine and mortality. Evidence for causal inference? Dan Med Bull 2000;47(4):271-82.

292. Grumbach K, Anderson GM, Luft HS, et al. Regionalization of cardiac surgery in the United States and Canada. Geographic access, choice, and outcomes. Jama 1995;274(16):1282-8.
293. Guerci AD, Spadaro LA, Goodman KJ, et al. Comparison of electron beam computed tomography scanning and conventional risk factor assessment for the prediction of angiographic coronary artery disease. J Am Coll Cardiol 1998;32(3):673-9.
294. Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997;28(12):2557-62.
295. Gueyffier F, Boissel JP, Pocock S, et al. Identification of risk factors in hypertensive patients: contribution of randomized controlled trials through an individual patient database. Circulation 1999;100(18):e88-94.
296. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997;126(10):761-7.
297. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens 1996;10(1):1-8.
298. Gunnell D, Harvey I, Smith L. The invasive management of angina: issues for consumers and commissioners. J Epidemiol Community Health 1995;49(4):335-43.
299. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. Jama 1992;268(11):1417-22.
300. Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 1998;82(12A):18U-23U; discussion 39U-41U.
301. Haberbosch W, Jantos C. Chlamydia pneumoniae infection is not an independent risk factor for arterial disease. Herz 2000;25(2):79-83.
302. Hachamovitch R, Berman DS, Kiat H, et al. Effective risk stratification using exercise myocardial perfusion SPECT in women: gender-related differences in prognostic nuclear testing. J Am Coll Cardiol 1996;28(1):34-44.
303. Hachamovitch R, Berman DS, Kiat H, et al. Value of stress myocardial perfusion single photon emission computed tomography in patients with normal resting electrocardiograms: an evaluation of incremental prognostic value and cost-effectiveness. Circulation 2002;105(7):823-9.
304. Haffner SM. Impaired glucose tolerance, insulin resistance and cardiovascular disease. Diabet Med 1997;14(Suppl 3):S12-8.
305. Hagberg JM, Park JJ, Brown MD. The role of exercise training in the treatment of hypertension: an update. Sports Med 2000;30(3):193-206.
306. Hamilton CA, Link KM, Salido TB, et al. Is imaging at intermediate doses necessary during dobutamine stress magnetic resonance imaging? J Cardiovasc Magn Reson 2001;3(4):297-302.
307. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000;31(7):1779-84.
308. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2000(2):CD001246.
309. Hannan EL, Kilburn H, Jr., O'Donnell JF, et al. Interracial access to selected cardiac procedures for patients hospitalized with coronary artery disease in New York State. Med Care 1991;29(5):430-41.
310. Hannan EL, Kumar D. Geographic variation in the utilization and choice of procedures for treating coronary artery disease in New York State. Ischaemic Heart Disease Patient Outcomes Research Team (PORT). J Health Serv Res Policy 1997;2(3):137-43.
311. Hansen EF, Andersen LT, Von Eyben FE. Cigarette smoking and age at first acute myocardial infarction, and influence of gender and extent of smoking. Am J Cardiol 1993;71(16):1439-42.
312. Hansen JF. Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. The Danish Study Group on Verapamil in Myocardial Infarction. J Cardiovasc Pharmacol 1991;18(Suppl 6):S20-5.
313. Hansen JF. Review of postinfarct treatment with verapamil: combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction. Danish Study Group on Verapamil in Myocardial Infarction. Cardiovasc Drugs Ther 1994;8(Suppl 3):543-7.

314. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755-62.
315. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999;21(4):325-35.
316. Harnick DJ, Cohen JL, Schechter CB, et al. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol 1998;81(12):1416-20.
317. Harris T, Cook EF, Garrison R, et al. Body mass index and mortality among nonsmoking older persons. The Framingham Heart Study. Jama 1988;259(10):1520-4.
318. Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000;57(3):326-32.
319. Hasdai D, Holmes DR, Jr., Topol EJ, et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. Eur Heart J 1999;20(2):128-35.
320. Haymart MR, Dickfeld T, Nass C, et al. Percutaneous coronary intervention vs. medical therapy: what are the implications for women? J Womens Health Gend Based Med 2002;11(4):347-55.
321. He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens Suppl 1999;17(2):S7-13.
322. Healy B. The Yentl syndrome. N Engl J Med 1991;325(4):274-6.
323. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Jama 1997;278(4):313-21.
324. Hebert PR, Hennekens CH. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med 2000;160(20):3123-7.
325. Heiat A, Vaccarino V, Krumholz HM. An evidence-based assessment of federal guidelines for overweight and obesity as they apply to elderly persons. Arch Intern Med 2001;161(9):1194-203.
326. Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38(2):478-85.
327. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30(1):27-34.
328. Heidenreich PA, McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. Am J Med 2001;110(3):165-74.
329. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. Jama 1999;281(20):1927-36.
330. Held PH, Teo KK, Yusuf S. Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction. Circulation 1990;82(5):1668-74.
331. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Bmj 1989;299(6709):1187-92.
332. Hennekens CH. Thrombolytic therapy: pre- and post-GISSI-2, ISIS-3, and GUSTO-1. Clin Cardiol 1994;17(1 Suppl 1):I15-7.
333. Hennekens CH, Albert CM, Godfried SL, et al. Adjunctive drug therapy of acute myocardial infarction--evidence from clinical trials. N Engl J Med 1996;335(22):1660-7.
334. Hermanson B, Omenn GS, Kronmal RA, et al. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. N Engl J Med 1988;319(21):1365-9.
335. Herold PM, Kinsella JE. Fish oil consumption and decreased risk of cardiovascular disease: a comparison of findings from animal and human feeding trials. Am J Clin Nutr 1986;43(4):566-98.
336. Hill K. The demography of menopause. Maturitas 1996;23(2):113-27.
337. Hillegass WB, Newman AR, Raco DL. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications. Pharmacoeconomics 2001;19(1):41-55.
338. Hlatky MA, Pryor DB, Harrell FE, Jr., et al. Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. Am J Med 1984;77(1):64-71.

339. Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1997;30(1):141-8.
340. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med 1999;341(4):226-32.
341. Hoes AW, Grobbee DE, Lubsen J. Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 1995;13(7):805-11.
342. Hoher M, Wohrle J, Grebe OC, et al. A randomized trial of elective stenting after balloon recanalization of chronic total occlusions. J Am Coll Cardiol 1999;34(3):722-9.
343. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3(2):213-9.
344. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis. Br Heart J 1993;69(1 Suppl):S42-7.
345. Holme I. Effects of lipid-lowering therapy on total and coronary mortality. Curr Opin Lipidol 1995;6(6):374-8.
346. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995;76(9):10C-17C.
347. Holme I. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. Control Clin Trials 1996;17(1):13-22.
348. Holme I, Ekelund LG, Hjermann I, et al. Quality-adjusted meta-analysis of the hypertension/coronary dilemma. Am J Hypertens 1994;7(8):703-12.
349. Holmes DR, Jr., Holubkov R, Vlietstra RE, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1988;12(5):1149-55.
350. Honan MB, Harrell FE, Jr., Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol 1990;16(2):359-67.
351. Horton HL, Marinchak RA, Rials SJ, et al. Gender differences in device therapy for malignant ventricular arrhythmias. Arch Intern Med 1995;155(21):2342-5.
352. Houghton T, Freemantle N, Cleland JG. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur J Heart Fail 2000;2(3):333-40.
353. Howard G, Manolio TA, Burke GL, et al. Does the association of risk factors and atherosclerosis change with age? An analysis of the combined ARIC and CHS cohorts. The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Study (CHS) investigators. Stroke 1997;28(9):1693-701.
354. Howes LG, Simons LA. Efficacy of drug intervention for lipids in the prevention of coronary artery disease. Aust N Z J Med 1994;24(1):107-12.
355. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159(10):1061-6.
356. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001;161(14):1717-23.
357. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67(5):968-77.
358. Huckell VF, Bernstein V, Cairns JA, et al. Angiotensin-converting enzyme inhibition in myocardial infarction--Part 1: Clinical data. Can J Cardiol 1997;13(2):161-9.
359. Hughes GC, Abdel-aleem S, Biswas SS, et al. Transmyocardial laser revascularization: experimental and clinical results. Can J Cardiol 1999;15(7):797-806.
360. Hughes GC, Annex BH, Yin B, et al. Transmyocardial laser revascularization limits in vivo adenoviral-mediated gene transfer in porcine myocardium. Cardiovasc Res 1999;44(1):81-90.
361. Hume AL, Barbour MM, Willey CJ, et al. Changing trends in antihypertensive therapy in two New England communities during the 1980s. Pharmacotherapy 1993;13(3):244-51.

362. Hunink MG, Kuntz KM, Fleischmann KE, et al. Noninvasive imaging for the diagnosis of coronary artery disease: focusing the development of new diagnostic technology. Ann Intern Med 1999;131(9):673-80.
363. Hussain KM, Kogan A, Estrada AQ, et al. Referral pattern and outcome in men and women undergoing coronary artery bypass surgery--a critical review. Angiology 1998;49(4):243-50.
364. Hutchinson LA, Pasternack PF, Baumann FG, et al. Is there detrimental gender bias in preoperative cardiac management of patients undergoing vascular surgery? Circulation 1994;90(5 Pt 2):II220-3.
365. Hutchinson RG, Watson RL, Davis CE, et al. Racial differences in risk factors for atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities. Angiology 1997;48(4):279-90.
366. Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994;121(5):355-62.
367. Ioannidis JP, Salem D, Chew PW, et al. Accuracy of imaging technologies in the diagnosis of acute cardiac ischemia in the emergency department: a meta-analysis. Ann Emerg Med 2001;37(5):471-7.
368. Iskandrian AE, Heo J, Nallamothu N. Detection of coronary artery disease in women with use of stress single-photon emission computed tomography myocardial perfusion imaging. J Nucl Cardiol 1997;4(4):329-35.
369. Izzat MB, West RR, Bryan AJ, et al. Coronary artery bypass surgery: current practice in the United Kingdom. Br Heart J 1994;71(4):382-5.
370. Jackson RE, Anderson W, Peacock WFt, et al. Effect of a patient's sex on the timing of thrombolytic therapy. Ann Emerg Med 1996;27(1):8-15.
371. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). Circulation 1998;98(13):1279-85.
372. Jacobs AK, Kelsey SF, Yeh W, et al. Documentation of decline in morbidity in women undergoing coronary angioplasty (a report from the 1993-94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry). National Heart, Lung, and Blood Institute. Am J Cardiol 1997;80(8):979-84.
373. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 1992;86(3):1046-60.
374. Jacobson TA. "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline? Ann Intern Med 2000;133(7):549-54.
375. Jaglal SB, Goel V, Naylor CD. Sex differences in the use of invasive coronary procedures in Ontario. Can J Cardiol 1994;10(2):239-44.
376. Janzon M, Levin LA, Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease. Eur Heart J 2002;23(1):31-40.
377. Jarrett RJ. The cardiovascular risk associated with impaired glucose tolerance. Diabet Med 1996;13(3 Suppl 2):S15-9.
378. Jenkins PL, Weinehall L, Erb TA, et al. The Norsjo-Cooperstown healthy heart project: a case study combining data from different studies without the use of meta-analysis. Scand J Public Health 2001;Suppl(56):40-5.
379. Johnson PA, Goldman L, Orav EJ, et al. Gender differences in the management of acute chest pain. Support for the "Yentl syndrome". J Gen Intern Med 1996;11(4):209-17.
380. Johnson PA, Lee TH, Cook EF, et al. Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med 1993;118(8):593-601.
381. Jolliffe JA, Rees K, Taylor RS, et al. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2000;4.
382. Jones RH, Hannan EL, Hammermeister KE, et al. Identification of preoperative variables needed for risk adjustment of short-term mortality after coronary artery bypass graft surgery. The Working Group Panel on the Cooperative CABG Database Project. J Am Coll Cardiol 1996;28(6):1478-87.
383. Jones RH, Kesler K, Phillips HR, 3rd, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg 1996;111(5):1013-25.
384. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. Jama 1996;275(20):1571-6.

385. Kannel WB, Cupples LA, Ramaswami R, et al. Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 1991;44(2):183-90.
386. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987;113(4):1006-10.
387. Kannel WB, D'Agostino RB, Belanger AJ. Risk reduction after quitting smoking. Quality of Life and Cardiovascular Care 1989:84-85.
388. Kannel WB, D'Agostino RB, Wilson PW, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120(3):672-6.
389. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 1985;5(6 Suppl):141B-149B.
390. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol 1979;44(1):53-9.
391. Kannel WB, Wilson PW. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992;124(3):768-74.
392. Katan MB. High-oil compared with low-fat, high-carbohydrate diets in the prevention of ischemic heart disease. Am J Clin Nutr 1997;66(4 Suppl):974S-979S.
393. Kawachi I, Colditz GA, Speizer FE, et al. A prospective study of passive smoking and coronary heart disease. Circulation 1997;95(10):2374-9.
394. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Ann Intern Med 1993;119(10):992-1000.
395. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risks of total mortality, stroke, and coronary heart disease incidence among women: a prospective cohort study. In: Burns DM, Garfinkel L, Samet JM, editors. Changes in cigarette-related disease risks and thier implications for prevention and control. Bethesda: National Cancer Institute; 1997. p. 531-65.
396. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med 1994;154(2):169-75.
397. Keelan PC, Bielak LF, Ashai K, et al. Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 2001;104(4):412-7.
398. Keenan CR, Chou TM. Revascularization in coronary artery disease. A review of randomized trial data. West J Med 1998;168(4):280-5.
399. Keil JE, Sutherland SE, Knapp RG, et al. Mortality rates and risk factors for coronary disease in black as compared with white men and women. N Engl J Med 1993;329(2):73-8.
400. Keil U. Coronary artery disease: the role of lipids, hypertension and smoking. Basic Res Cardiol 2000;95(Suppl 1):I52-8.
401. Kellett J, Clarke J. Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction. Med Decis Making 1995;15(4):297-310.
402. Kelly R. Selections from current literature: treatment of hypertension. Fam Pract 1992;9(1):104-8.
403. Kelsey SF, James M, Holubkov AL, et al. Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993;87(3):720-7.
404. Kennedy J, Shavelle R, Wang S, et al. Coronary calcium and standard risk factors in symptomatic patients referred for coronary angiography. Am Heart J 1998;135(4):696-702.
405. Ketola E, Sipila R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med 2000;32(4):239-51.
406. Khan SS, Nessim S, Gray R, et al. Increased mortality of women in coronary artery bypass surgery: evidence for referral bias. Ann Intern Med 1990;112(8):561-7.
407. Kilaru PK, Kelly RF, Calvin JE, et al. Utilization of coronary angiography and revascularization after acute myocardial infarction in men and women risk stratified by the American College of Cardiology/American Heart Association guidelines. J Am Coll Cardiol 2000;35(4):974-9.
408. Kim RJ, Hillenbrand HB, Judd RM. Evaluation of myocardial viability by MRI. Herz 2000;25(4):417-30.
409. Kimmelstiel C, Goldberg RJ. Congestive heart failure in women: focus on heart failure due to coronary artery disease and diabetes. Cardiology 1990;77(Suppl 2):71-9.
410. King SB, 3rd. The impact of performing a clinical trial on patient outcomes: lessons from the Emory Angioplasty vs. Surgery Trial. Trans Am Clin Climatol Assoc 1995;107:68-77; discussion 77-8.

411. Kinn JW, O'Neill WW, Benzuly KH, et al. Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction. Cathet Cardiovasc Diagn 1997;42(2):151-7.
412. Kinney MR, Burfitt SN, Stullenbarger E, et al. Quality of life in cardiac patient research: a meta-analysis. Nurs Res 1996;45(3):173-80.
413. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens 2000;18(5):629-42.
414. Kjeldsen SE, Warnold I, Hansson L. Influence of gender on prevention of myocardial infarction by antihypertensives and acetylsalicylic acid: the HOT study. J Gend Specif Med 2000;3(8):35-8.
415. Kloner RA, Vetrovec GW, Materson BJ, et al. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am J Cardiol 1998;81(2):163-9.
416. Klungel OH, de Boer A, Paes AH, et al. Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. J Hypertens 1997;15(6):591-600.
417. Klungel OH, de Boer A, Paes AH, et al. Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. J Hypertens 1998;16(10):1545-53.
418. Klungel OH, Paes AH, de Boer A, et al. Sex differences in the medication choice for hypertension in general practice. A study with written case simulations. Pharm World Sci 2000;22(4):140-6.
419. Knapp RG, Sutherland SE, Keil JE, et al. A comparison of the effects of cholesterol on CHD mortality in black and white women: twenty-eight years of follow-up in the Charleston Heart Study. J Clin Epidemiol 1992;45(10):1119-29.
420. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
421. Ko W, Gold JP, Lazzaro R, et al. Survival analysis of octogenarian patients with coronary artery disease managed by elective coronary artery bypass surgery versus conventional medical treatment. Circulation 1992;86(5 Suppl):II191-7.
422. Koenig W. Fibrinogen and coronary risk. Curr Cardiol Rep 1999;1(2):112-8.
423. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98(25):2829-35.
424. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999;100(20):2049-53.
425. Kotler TS, Diamond GA. Exercise thallium-201 scintigraphy in the diagnosis and prognosis of coronary artery disease. Ann Intern Med 1990;113(9):684-702.
426. Krumholz HM, Douglas PS, Lauer MS, et al. Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? Ann Intern Med 1992;116(10):785-90.
427. Kudenchuk PJ, Maynard C, Martin JS, et al. Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Cardiol 1996;78(1):9-14.
428. Kuller LH, Simkin-Silverman LR, Wing RR, et al. Women's Healthy Lifestyle Project: A randomized clinical trial: results at 54 months. Circulation 2001;103(1):32-7.
429. Kuntz KM, Tsevat J, Weinstein MC, et al. Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction. Jama 1999;282(23):2246-51.
430. Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999;83(5):660-6.
431. La Vecchia C. Sex hormones and cardiovascular risk. Hum Reprod 1992;7(2):162-7.
432. LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991;324(23):1619-25.
433. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. Jama 1999;282(24):2340-6.
434. Larsen J, Vaccheri A, Andersen M, et al. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000;49(5):463-71.
435. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995;92(10):3132-7.
436. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin:

systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000;35(7):1801-7.
437. Lau GS, Chan JC, Chu PL, et al. Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong. Ann Pharmacother 1996;30(3):232-7.
438. Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327(4):248-54.
439. Lau J, Ioannidis JP, Balk EM, et al. Diagnosing acute cardiac ischemia in the emergency department: a systematic review of the accuracy and clinical effect of current technologies. Ann Emerg Med 2001;37(5):453-60.
440. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Bmj 1994;308(6925):367-72.
441. Lear JT, Lawrence IG, Burden AC, et al. A comparison of stress test referral rates and outcome between Asians and Europeans. J R Soc Med 1994;87(11):661-2.
442. Lear JT, Lawrence IG, Pohl JE, et al. Myocardial infarction and thrombolysis: a comparison of the Indian and European populations on a coronary care unit. J R Coll Physicians Lond 1994;28(2):143-7.
443. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98(12):1184-91.
444. Lee IM, Rexrode KM, Cook NR, et al. Physical activity and coronary heart disease in women: is "no pain, no gain" passe? Jama 2001;285(11):1447-54.
445. Lee S, Spencer A. Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. J Fam Pract 2001;50(6):499-504.
446. Lee TH, Boucher CA. Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med 2001;344(24):1840-5.
447. Lee WL, Cheung AM, Cape D, et al. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000;23(7):962-8.
448. Leis HP, Jr. The relationship of diet to cancer, cardiovascular disease and longevity. Int Surg 1991;76(1):1-5.
449. Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002;143(2):301-7.
450. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986;111(2):383-90.
451. Lewington S, MacMahon S. Blood pressure, cholesterol, and common causes of death: a review. Prospective Studies Collaboration. Am J Hypertens 1999;12(10 Pt 2):96S-98S.
452. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998;32(1):140-6.
453. Lewsey JD, Murray GD, Leyland AH, et al. Comparing outcomes of percutaneous transluminal coronary angioplasty with coronary artery bypass grafting; can routine health service data complement and enhance randomized controlled trials? Eur Heart J 1999;20(23):1731-5.
454. Lieu TA, Gurley RJ, Lundstrom RJ, et al. Primary angioplasty and thrombolysis for acute myocardial infarction: an evidence summary. J Am Coll Cardiol 1996;27(3):737-50.
455. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1997;30(1):149-56.
456. Lincoff AM, Califf RM, Ellis SG, et al. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. J Am Coll Cardiol 1993;22(7):1780-7.
457. Link N, Tanner M. Coronary artery disease: Part 1. Epidemiology and diagnosis. West J Med 2001;174(4):257-61.
458. Lip GY, Beevers DG. Alcohol, hypertension, coronary disease and stroke. Clin Exp Pharmacol Physiol 1995;22(3):189-94.

459. Lobo RA. Lipids, clotting factors, and diabetes: endogenous risk factors for cardiovascular disease. Am J Obstet Gynecol 1988;158(6 Pt 2):1584-91.
460. Loewen P, Sunderji R, Gin K. The efficacy and safety of combination warfarin and ASA therapy: a systematic review of the literature and update of guidelines. Can J Cardiol 1998;14(5):717-26.
461. Lonn E, Roccaforte R, Yi Q, et al. Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol 2002;40(4):693.
462. Lonn EM, Yusuf S. Evidence based cardiology: emerging approaches in preventing cardiovascular disease. Bmj 1999;318(7194):1337-41.
463. Lowel H, Lewis M, Hormann A, et al. Case finding, data quality aspects and comparability of myocardial infarction registers: results of a south German register study. J Clin Epidemiol 1991;44(3):249-60.
464. Lubsen J. The calcium channel antagonist debate: recent developments. Eur Heart J 1998;19(Suppl I):I3-7.
465. MacMahon S, Sharpe N. Long-term antiplatelet therapy for the prevention of vascular disease. Med J Aust 1991;154(7):477-80.
466. Maggioni AP, Sessa F, Latini R, et al. Treatment of acute myocardial infarction today. Am Heart J 1997;134(2 Pt 2):S9-14.
467. Magrini N, Einarson T, Vaccheri A, et al. Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997;53(3-4):185-9.
468. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996;77(8):551-6.
469. Mahaffey KW, Granger CB, Toth CA, et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30(7):1606-10.
470. Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 2000;22(3):275-9.
471. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;14(12):711-7.
472. Makela P, Valkonen T, Poikolainen K. Estimated numbers of deaths from coronary heart disease "caused" and "prevented" by alcohol: an example from Finland. J Stud Alcohol 1997;58(5):455-63.
473. Malenka DJ, O'Rourke D, Miller MA, et al. Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty. The Northern New England Cardiovascular Disease Study Group. Am Heart J 1999;137(4 Pt 1):632-8.
474. Malhotra S, Karan RS, Bhargava VK, et al. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina. Indian Heart J 2001;53(2):197-202.
475. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102(9):1014-9.
476. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 1992;2(1-2):161-76.
477. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151(6):1141-7.
478. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990;322(13):882-9.
479. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341(9):650-8.
480. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. Jama 1991;266(4):521-7.
481. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med 1992;326(21):1406-16.
482. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995;333(11):677-85.

483. Marber M, MacRae C, Joy M. Delay to invasive investigation and revascularisation for coronary heart disease in south west Thames region: a two tier system? Bmj 1991;302(6786):1189-91.
484. Marchioli R, Marfisi RM, Carinci F, et al. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med 1996;156(11):1158-72.
485. Marine JE, Freedberg KA, Davidoff R. Cost-effectiveness of stress-echocardiography. Cardiol Clin 1999;17(3):583-95, x.
486. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332(21):1418-24.
487. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994;89(5):2015-25.
488. Mark DB, Shaw L, Harrell FE, Jr., et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991;325(12):849-53.
489. Maron DJ. Percutaneous coronary intervention versus medical therapy for coronary heart disease. Curr Atheroscler Rep 2000;2(4):290-6.
490. Martikainen J, Klaukka T, Reunanen A, et al. Recent trends in the consumption of lipid-lowering drugs in Finland. J Clin Epidemiol 1996;49(12):1453-57.
491. Marwick TH, Shaw LJ, Lauer MS, et al. The noninvasive prediction of cardiac mortality in men and women with known or suspected coronary artery disease. Economics of Noninvasive Diagnosis (END) Study Group. Am J Med 1999;106(2):172-8.
492. Marz W, Wieland H. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? Herz 2000;25(2):117-25.
493. Mathis AS. Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes. Ann Pharmacother 2000;34(2):208-27.
494. Matsui K, Polanczyk CA, Gaspoz JM, et al. Management of patients with acute myocardial infarction at five academic medical centers: clinical characteristics, resource utilization, and outcome. J Investig Med 1999;47(3):134-40.
495. Matsuo T, Kobayashi H, Kario K, et al. Fibrin D-dimer in thrombogenic disorders. Semin Thromb Hemost 2000;26(1):101-7.
496. Maynard C, Althouse R, Cerqueira M, et al. Underutilization of thrombolytic therapy in eligible women with acute myocardial infarction. Am J Cardiol 1991;68(5):529-30.
497. Maynard C, Litwin PE, Martin JS, et al. Gender differences in the treatment and outcome of acute myocardial infarction. Results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med 1992;152(5):972-6.
498. McGlynn EA, Naylor CD, Anderson GM, et al. Comparison of the appropriateness of coronary angiography and coronary artery bypass graft surgery between Canada and New York State. Jama 1994;272(12):934-40.
499. McGregor M, Brophy JM. Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty. Can J Cardiol 1999;15(2):201-7.
500. McLeod AL, Northridge DB, Uren NG. Ultrasound guided stenting. Heart 2001;85(6):605-6.
501. McNamara DJ. Dietary cholesterol and atherosclerosis. Biochim Biophys Acta 2000;1529(1-3):310-20.
502. Mehilli J, Kastrati A, Dirschinger J, et al. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. Jama 2000;284(14):1799-805.
503. Mehta RH, Bates ER. Coronary stent implantation in acute myocardial infarction. Am Heart J 1999;137(4 Pt 1):603-11.
504. Mehta RH, Bossone E, Eagle KA. Current concepts in secondary prevention after acute myocardial infarction. Herz 2000;25(1):47-60.
505. Mehta SR, Eikelboom JW, Natarajan MK, et al. Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol 2001;37(1):37-43.
506. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21(24):2033-41.

507. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33.
508. Meilahn EN. Hemostatic factors and risk of cardiovascular disease in women. An overview. Arch Pathol Lab Med 1992;116(12):1313-7.
509. Meleady R, Graham I. Plasma homocysteine as a cardiovascular risk factor: causal, consequential, or of no consequence? Nutr Rev 1999;57(10):299-305.
510. Mendelson G, Aronow WS. Underutilization of measurement of serum low-density lipoprotein cholesterol levels and of lipid-lowering therapy in older patients with manifest atherosclerotic disease. J Am Geriatr Soc 1998;46(9):1128-31.
511. Merlo J, Ranstam J, Rastam L, et al. Age standardisation of drug utilisation: comparisons of different methods using cardiovascular drug data from Sweden and Spain. Eur J Clin Pharmacol 1994;46(5):393-8.
512. Messeri P, Workman S, Saunders C, et al. The application of meta-analysis in assessing racial differences in the effects of antihypertensive medication. J Natl Med Assoc 1997;89(7):477-85.
513. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995;123(11):888-9.
514. Michels KB, Rosner BA, Manson JE, et al. Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: the Nurses' Health Study. Circulation 1998;97(16):1540-8.
515. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995;91(2):476-85.
516. Midgette AS, O'Connor GT, Baron JA, et al. Effect of intravenous streptokinase on early mortality in patients with suspected acute myocardial infarction. A meta-analysis by anatomic location of infarction. Ann Intern Med 1990;113(12):961-8.
517. Midgette AS, Wong JB, Beshansky JR, et al. Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 1994;14(2):108-17.
518. Mieres JH, Udelson JE. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999;84(12):1454-6.
519. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96(12):4211-8.
520. Millard PS, Sturrock WA. Heparin and thrombolysis in acute MI. J Fam Pract 1996;43(1):20-1.
521. Miller M, Byington R, Hunninghake D, et al. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Arch Intern Med 2000;160(3):343-7.
522. Miller TD, Roger VL, Hodge DO, et al. Gender differences and temporal trends in clinical characteristics, stress test results and use of invasive procedures in patients undergoing evaluation for coronary artery disease. J Am Coll Cardiol 2001;38(3):690-7.
523. Miller TD, Roger VL, Milavetz JJ, et al. Assessment of the exercise electrocardiogram in women versus men using tomographic myocardial perfusion imaging as the reference standard. Am J Cardiol 2001;87(7):868-73.
524. Milne R. HMG CO-A reductase inhibitor treatment in the prevention of coronary heart disease. Southampton: Wessex Institute for Health Research and Development; 1997. Report No.: DEC Report No. 72.
525. Moen EK, Asher CR, Miller DP, et al. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Womens Health 1997;6(3):285-93.
526. Montagne O, Vedel I, Durand-Zaleski I. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations. Clin Ther 1999;21(11):2027-35.

527. Montague T, Tsuyuki R, Burton J, et al. Prevention and regression of coronary atherosclerosis. Is it safe and efficacious therapy? Chest 1994;105(3):718-26.
528. Moore RD, Pearson TA. Moderate alcohol consumption and coronary artery disease. A review. Medicine (Baltimore) 1986;65(4):242-67.
529. Morris JL, Cowan JC. Nitrates in myocardial infarction: a current perspective. Can J Cardiol 1995;11(Suppl B):5B-10B.
530. Morrison C, Woodward M, Leslie W, et al. Effect of socioeconomic group on incidence of, management of, and survival after myocardial infarction and coronary death: analysis of community coronary event register. Bmj 1997;314(7080):541-6.
531. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. Jama 2000;283(20):2686-92.
532. Moulds RF. Measurement of cost-effectiveness of drug therapy: a review of the treatment of hypertension. Med J Aust 1990;153(Suppl):S4-6.
533. Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. Bmj 2001;322(7277):11-5.
534. Nallamothu BK, Saint S, Bielak LF, et al. Electron-beam computed tomography in the diagnosis of coronary artery disease: a meta-analysis. Arch Intern Med 2001;161(6):833-8.
535. Naylor CD, Ugnat AM, Weinkauf D, et al. Coronary artery bypass grafting in Canada: What is its rate of use? Which rate is right? Cmaj 1992;146(6):851-9.
536. Neal B, MacMahon S. An overview of 37 randomised trials of blood pressure lowering agents among 270,000 individuals. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Clin Exp Hypertens 1999;21(5-6):517-29.
537. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356(9246):1955-64.
538. Nelson KM, Yeager BF. What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction? Ann Pharmacother 1996;30(9):986-93.
539. Nemergut C, Cheng JW. Use of direct thrombin inhibitors in acute coronary syndrome. Clin Ther 2000;22(8):937-48; discussion 898.
540. Newby K. Clinical outcomes according to time to treatment. Clin Cardiol 1997;20(11 Suppl 3):III11-5.
541. Nielsen WB, Vestbo J, Jensen GB. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. J Hum Hypertens 1995;9(3):175-80.
542. Nilsson R. A qualitative and quantitative risk assessment of snuff dipping. Regul Toxicol Pharmacol 1998;28(1):1-16.
543. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation 1996;93(3):450-6.
544. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80(2):234-44.
545. O'Connor GT, Morton JR, Diehl MJ, et al. Differences between men and women in hospital mortality associated with coronary artery bypass graft surgery. The Northern New England Cardiovascular Disease Study Group. Circulation 1993;88(5 Pt 1):2104-10.
546. O'Malley PG, Taylor AJ, Jackson JL, et al. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol 2000;85(8):945-8.
547. O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol 2000;36(1):326-40.
548. O'Shea EB. A study of the use of aspirin by general practitioners in suspected myocardial infarction. Ir Med J 2001;94(2):48-50, 52.
549. Okin PM, Kligfield P. Gender-specific criteria and performance of the exercise electrocardiogram. Circulation 1995;92(5):1209-16.

550. Olatidoye AG, Wu AH, Feng YJ, et al. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 1998;81(12):1405-10.
551. Oldridge NB, Guyatt GH, Fischer ME, et al. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. Jama 1988;260(7):945-50.
552. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. Jama 1996;276(10):811-5.
553. Oliver MF. Cholesterol and coronary disease--outstanding questions. Cardiovasc Drugs Ther 1992;6(2):131-6.
554. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992;13(1):28-32.
555. Omenn GS, Anderson KW, Kronmal RA, et al. The temporal pattern of reduction of mortality risk after smoking cessation. Am J Prev Med 1990;6(5):251-7.
556. Onder G, Gambassi G, Landi F, et al. Trends in antihypertensive drugs in the elderly: the decline of thiazides. J Hum Hypertens 2001;15(5):291-7.
557. Opie LH, Yusuf S, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog Cardiovasc Dis 2000;43(2):171-96.
558. Orchard TJ. The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med 1996;28(4):323-33.
559. Orlandini A, Tuero E, Paolasso E, et al. Usefulness of pharmacologic stress echocardiography in a chest pain center. Am J Cardiol 2000;86(11):1247-50, A6.
560. Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000;140(6):917-27.
561. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334(21):1349-55.
562. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344(22):1651-8.
563. Paganini-Hill A, Hsu G. Smoking and mortality among residents of a California retirement community. Am J Public Health 1994;84(6):992-5.
564. Pagley PR, Yarzebski J, Goldberg R, et al. Gender differences in the treatment of patients with acute myocardial infarction. A multihospital, community-based perspective. Arch Intern Med 1993;153(5):625-9.
565. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000;356(9246):1949-54.
566. Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;23(7):888-92.
567. Pancholy SB, Fattah AA, Kamal AM, et al. Independent and incremental prognostic value of exercise thallium single-photon emission computed tomographic imaging in women. J Nucl Cardiol 1995;2(2 Pt 1):110-6.
568. Pearce KA, Furberg CD, Rushing J. Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. Arch Fam Med 1995;4(11):943-9; discussion 950.
569. Pearson ML, Kahn KL, Harrison ER, et al. Differences in quality of care for hospitalized elderly men and women. Jama 1992;268(14):1883-9.
570. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998;21(9):633-41.
571. Perlman JA, Wolf PH, Ray R, et al. Cardiovascular risk factors, premature heart disease, and all-cause mortality in a cohort of northern California women. Am J Obstet Gynecol 1988;158(6 Pt 2):1568-74.
572. Perreault S, Hamilton VH, Lavoie F, et al. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1997;10(6):787-94.
573. Peterson ED, Lansky AJ, Anstrom KJ, et al. Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network Database. Am Heart J 2000;139(2 Pt 1):198-207.

574. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. Ann N Y Acad Sci 1993;703:314-40.
575. Petticrew M, McKee M, Jones J. Coronary artery surgery: are women discriminated against? Bmj 1993;306(6886):1164-6.
576. Pfeffer MA, Moye LA, Braunwald E, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. Jama 1991;266(4):528-32.
577. Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 1998;32(3):634-40.
578. Philbin EF, McCullough PA, DiSalvo TG, et al. Underuse of invasive procedures among Medicaid patients with acute myocardial infarction. Am J Public Health 2001;91(7):1082-8.
579. Pi-Sunyer FX. Comorbidities of overweight and obesity: current evidence and research issues. Med Sci Sports Exerc 1999;31(11 Suppl):S602-8.
580. Picano E, Bedetti G, Varga A, et al. The comparable diagnostic accuracies of dobutamine-stress and dipyridamole-stress echocardiographies: a meta-analysis. Coron Artery Dis 2000;11(2):151-9.
581. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Bmj 2000;321(7267):983-6.
582. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med 1995;333(9):565-72.
583. Pilote L, Granger C, Armstrong PW, et al. Differences in the treatment of myocardial infarction between the United States and Canada. A survey of physicians in the GUSTO trial. Med Care 1995;33(6):598-610.
584. Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346(8984):1184-9.
585. Pocock SJ, McCormack V, Gueyffier F, et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ 2001;323(7304):75-81.
586. Podrid PJ. Proarrhythmia, a serious complication of antiarrhythmic drugs. Curr Cardiol Rep 1999;1(4):289-96.
587. Popma JJ, Chuang YC, Satler LF, et al. Primary coronary angioplasty in patients with acute myocardial infarction. Tex Heart Inst J 1994;21(2):148-57.
588. Popma JJ, Topol EJ. Adjuncts to thrombolysis for myocardial reperfusion. Ann Intern Med 1991;115(1):34-44.
589. Porsova-Dutoit I, Sulcova J, Starka L. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiol Res 2000;49(Suppl 1):S43-56.
590. Port S, Demer L, Jennrich R, et al. Systolic blood pressure and mortality. Lancet 2000;355(9199):175-80.
591. Potts JL, Thomas J. Traditional coronary risk factors in African Americans. Am J Med Sci 1999;317(3):189-92.
592. Prescott E, Hippe M, Schnohr P, et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998;316(7137):1043-7.
593. Pretre R, Turina MI. Analysis of trials of surgery vs angioplasty in myocardial revascularization. Semin Interv Cardiol 1999;4(4):235-43.
594. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. Bmj 2000;321(7272):1322-5.
595. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132(10):769-79.
596. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. Jama 1997;277(9):739-45.
597. Puletti M, Sunseri L, Curione M, et al. Acute myocardial infarction: sex-related differences in prognosis. Am Heart J 1984;108(1):63-6.
598. Quan A, Kerlikowske K, Gueyffier F, et al. Efficacy of treating hypertension in women. J Gen Intern Med 1999;14(12):718-29.
599. Quan A, Kerlikowske K, Gueyffier F, et al. Pharmacotherapy for hypertension in women of different races. Cochrane Database Syst Rev 2000(3):CD002146.

600. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002;106(3):379-85.
601. Raggi P. Coronary calcium on electron beam tomography imaging as a surrogate marker of coronary artery disease. Am J Cardiol 2001;87(4A):27A-34A.
602. Raine RA, Crayford TJ, Chan KL, et al. Gender differences in the treatment of patients with acute myocardial ischemia and infarction in England. Int J Technol Assess Health Care 1999;15(1):136-46.
603. Ramsey DJ, Goff DC, Wear ML, et al. Sex and ethnic differences in use of myocardial revascularization procedures in Mexican Americans and non-Hispanic whites: the Corpus Christi Heart Project. J Clin Epidemiol 1997;50(5):603-9.
604. Rao AV. Coronary heart disease risk factors in women: focus on gender differences. J La State Med Soc 1998;150(2):67-72.
605. Redberg RF, Rifai N, Gee L, et al. Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol 2000;36(1):39-43.
606. Rembold CM. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. J Fam Pract 1996;42(6):577-86.
607. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. Jama 1998;280(21):1843-8.
608. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103(13):1813-8.
609. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98(8):731-3.
610. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97(20):2007-11.
611. Ridker PM, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med 1998;46(8):391-5.
612. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342(12):836-43.
613. Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991;114(10):835-9.
614. Ridker PM, O'Donnell C, Marder VJ, et al. Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med 1993;119(6):530-2.
615. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100(3):230-5.
616. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001;47(3):403-11.
617. Rifkind BM. High-density lipoprotein cholesterol and coronary artery disease: survey of the evidence. Am J Cardiol 1990;66(6):3A-6A.
618. Rihal CS, Yusuf S. Chronic coronary artery disease: drugs, angioplasty, or surgery? Bmj 1996;312(7026):265-6.
619. Rill V, Brown DL. Practice of coronary angioplasty in California in 1995 : comparison to 1989 and impact of coronary stenting. Circulation 1999;99(21):e12.
620. Rivetti LA, Gandra SM. An intraluminal shunt for off-pump coronary artery bypass grafting. Report of 501 consecutive cases and review of the technique. Heart Surg Forum 1998;1(1):30-6.
621. Rochon PA, Clark JP, Binns MA, et al. Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction. Cmaj 1998;159(4):321-7.
622. Rockhill B, Willett WC, Manson JE, et al. Physical activity and mortality: a prospective study among women. Am J Public Health 2001;91(4):578-83.
623. Roger VL, Farkouh ME, Weston SA, et al. Sex differences in evaluation and outcome of unstable angina. Jama 2000;283(5):646-52.
624. Roger VL, Pellikka PA, Bell MR, et al. Sex and test verification bias. Impact on the diagnostic value of exercise echocardiography. Circulation 1997;95(2):405-10.
625. Roig E, Castaner A, Simmons B, et al. In-hospital mortality rates from acute myocardial infarction by race in U.S. hospitals: findings from the National Hospital Discharge Survey. Circulation 1987;76(2):280-8.

626. Rojas-Fernandez CH, Kephart GC, Sketris IS, et al. Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey. Can J Cardiol 1999;15(3):291-6.
627. Rosamond WD, Shahar E, McGovern PG, et al. Trends in coronary thrombolytic therapy for acute myocardial infarction (the Minnesota Heart Survey Registry, 1990 to 1993). Am J Cardiol 1996;78(3):271-7.
628. Rosano GM, Panina G. Oestrogens and the heart. Therapie 1999;54(3):381-5.
629. Rosenberg L, Hennekens CH, Rosner B, et al. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981;139(1):47-51.
630. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992;19(3):671-7.
631. Rubins HB. Cholesterol in patients with coronary heart disease: how low should we go? J Gen Intern Med 1995;10(8):464-71.
632. Ruilope LM, Suarez C. How should we treat hypertensive women with cardiac and renal impairment? Am J Hypertens 1997;10(10 Pt 2):242S-246S.
633. Rumberger JA, Brundage BH, Rader DJ, et al. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc 1999;74(3):243-52.
634. Ryan TJ, Ryan TJ, Jr., Jacobs AK. Primary PTCA versus thrombolytic therapy: an evidence-based summary. Am Heart J 1999;138(2 Pt 2):S96-104.
635. Sacks FM. Lipid-lowering therapy in acute coronary syndromes. Jama 2001;285(13):1758-60.
636. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-9.
637. Sacks HS, Chalmers TC, Berk AA, et al. Should mild hypertension be treated? An attempted meta-analysis of the clinical trials. Mt Sinai J Med 1985;52(4):265-70.
638. Sadowski ZP, Alexander JH, Skrabucha B, et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am Heart J 1999;137(5):792-8.
639. Safstrom K, Lindahl B, Swahn E. Risk stratification in unstable coronary artery disease--exercise test and troponin T from a gender perspective. FRISC-Study Group. Fragmin during InStability in Coronary artery disease. J Am Coll Cardiol 2000;35(7):1791-800.
640. Saha S, Stettin GD, Redberg RF. Gender and willingness to undergo invasive cardiac procedures. J Gen Intern Med 1999;14(2):122-5.
641. Salomaa V, Miettinen H, Niemela M, et al. Relation of socioeconomic position to the case fatality, prognosis and treatment of myocardial infarction events; the FINMONICA MI Register Study. J Epidemiol Community Health 2001;55(7):475-82.
642. Sane DC, Stump DC, Topol EJ, et al. Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Circulation 1991;83(1):170-5.
643. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85(3):265-71.
644. Santana-Boado C, Candell-Riera J, Castell-Conesa J, et al. Diagnostic accuracy of technetium-99m-MIBI myocardial SPECT in women and men. J Nucl Med 1998;39(5):751-5.
645. Santiago P, Vacek JL, Rosamond TL. Dobutamine stress echocardiography: clinical utility and predictive value at various infusion rates. Am Heart J 1994;128(4):804-8.
646. Savoie I, Wright J, Bassett K. Lipid lowering therapy. Vancouver: BC Office of Health Technology Assessment, Centre for Health Services and Policy Research, University of British Columbia, Finnish Office for Health Care Technolog Assessment (FinOHTA); 1998. Report No.: 1896256112.
647. Schildkraut JM, Myers RH, Cupples LA, et al. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol 1989;64(10):555-9.
648. Schneider EC, Leape LL, Weissman JS, et al. Racial differences in cardiac revascularization rates: does "overuse" explain higher rates among white patients? Ann Intern Med 2001;135(5):328-37.
649. Scott IA, Harden H, Coory M. What are appropriate rates of invasive procedures following acute myocardial infarction? A systematic review. Med J Aust 2001;174(3):130-6.

650. Selker HP, Zalenski RJ, Antman EM, et al. An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: a report from a National Heart Attack Alert Program Working Group. Ann Emerg Med 1997;29(1):13-87.
651. Senior R, Soman P, Khattar RS, et al. Prognostic value of dobutamine stress echocardiography in patients undergoing diagnostic coronary arteriography. Am J Cardiol 1997;79(12):1610-4.
652. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344(15):1117-24.
653. Seymour RA, Steele JG. Is there a link between periodontal disease and coronary heart disease? Br Dent J 1998;184(1):33-8.
654. Shahar E, Folsom AR, Romm FJ, et al. Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1996;131(5):915-22.
655. Shapira I, Fisman EZ, Drory Y, et al. Acute myocardial infarction in patients who have had coronary artery bypass surgery. South Med J 1997;90(11):1129-32.
656. Sharrett AR, Patsch W, Sorlie PD, et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1994;14(7):1098-104.
657. Shavelle DM, Budoff MJ, LaMont DH, et al. Exercise testing and electron beam computed tomography in the evaluation of coronary artery disease. J Am Coll Cardiol 2000;36(1):32-8.
658. Shaw LJ, Eagle KA, Gersh BJ, et al. Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratification before vascular surgery. J Am Coll Cardiol 1996;27(4):787-98.
659. Shaw LJ, Hachamovitch R, Redberg RF. Current evidence on diagnostic testing in women with suspected coronary artery disease: choosing the appropriate test. Cardiol Rev 2000;8(1):65-74.
660. Shaw LJ, Miller DD, Romeis JC, et al. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med 1994;120(7):559-66.
661. Shea S, Cook EF, Kannel WB, et al. Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study. Circulation 1985;71(1):22-30.
662. Shepherd J. New evidence, new guidelines. Atherosclerosis 1998;140(2):197-8.
663. Sherman SE, D'Agostino RB, Cobb JL, et al. Physical activity and mortality in women in the Framingham Heart Study. Am Heart J 1994;128(5):879-84.
664. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3(3):351-7.
665. Shinton RA, Beevers DG. A meta-analysis of mortality and coronary prevention in hypertensive patients treated with beta-receptor blockers. J Hum Hypertens 1990;4(Suppl 2):31-4.
666. Silberberg JS, Henry DA. The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 2. Implications for heart disease prevention in Australia. Med J Aust 1991;155(10):670-4.
667. Silberberg JS, Henry DA. The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 1. A meta-analysis of cholesterol-lowering trials. Med J Aust 1991;155(10):665-6, 669-70.
668. Sim I, Gupta M, McDonald K, et al. A meta-analysis of randomized trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty in multivessel coronary artery disease. Am J Cardiol 1995;76(14):1025-9.
669. Simes RJ. Low cholesterol and risk of non-coronary mortality. Aust N Z J Med 1994;24(1):113-9.
670. Simons-Morton DG, Calfas KJ, Oldenburg B, et al. Effects of interventions in health care settings on physical activity or cardiorespiratory fitness. Am J Prev Med 1998;15(4):413-30.
671. Sketris IS, Kephart GC, Hicks VA, et al. Prescribing patterns of antilipemic drugs and prevalence of hypercholesterolemia in the Nova Scotia population more than 65 years old. Ann Pharmacother 1995;29(6):576-81.
672. Smith BJ. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase. J Accid Emerg Med 1999;16(6):407-11.
673. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. Bmj 1993;306(6889):1367-73.
674. Solomon AJ, Gersh BJ. Management of chronic stable angina: medical therapy, percutaneous transluminal coronary angioplasty, and coronary artery bypass graft surgery. Lessons from the randomized trials. Ann Intern Med 1998;128(3):216-23.

675. Soma MR, Baetta R, Crosignani P. The menopause and lipid metabolism: strategies for cardiovascular disease prevention. Curr Opin Lipidol 1997;8(4):229-35.
676. Soriano JB, Hoes AW, Meems L, et al. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997;39(5):445-56.
677. Sorlie PD, Sharrett AR, Patsch W, et al. The relationship between lipids/lipoproteins and atherosclerosis in African Americans and whites: the Atherosclerosis Risk in Communities Study. Ann Epidemiol 1999;9(3):149-58.
678. Sowers KM, Sowers JR. Obesity, hypertension, and vas cular disease. Curr Hypertens Rep 1999;1(2):140-4.
679. Spinler SA, Cziraky MJ. Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother 1994;28(3):343-51.
680. Spinler SA, Nawarskas JJ. Low-molecular-weight heparins for acute coronary syndromes. Ann Pharmacother 1998;32(1):103-10.
681. Spurgeon A, Harrington JM, Cooper CL. Health and safety problems associated with long working hours: a review of the current position. Occup Environ Med 1997;54(6):367-75.
682. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350(9080):757-64.
683. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355(9207):865-72.
684. Staessen JA, Ginocchio G, Wang JG, et al. Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk 1997;4(5-6):401-22.
685. Staessen JA, Kuznetsova T, Wang JG, et al. M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens 1999;17(1):9-17.
686. Staessen JA, Wang JG, Ginocchio G, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997;15(12 Pt 2):1579-92.
687. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20(1):47-63.
688. Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease. A review. Ann N Y Acad Sci 1990;592:193-203; discussion 257-62.
689. Stason W, Schmid CH, Caubet JF, et al. Searching for signals: mortality and cardiovascular events in published randomized control trials of nifedipine in ischemic heart disease and hypertension. J Hypertens Suppl 1996;14(2):S5-7.
690. Stason WB, Schmid CH, Niedzwiecki D, et al. Safety of nifedipine in angina pectoris: a meta-analysis. Hypertension 1999;33(1):24-31.
691. Stason WB, Schmid CH, Niedzwiecki D, et al. Safety of nifedipine in patients with hypertension: a meta-analysis. Hypertension 1997;30(1 Pt 1):7-14.
692. Stefanick ML, Mackey S, Sheehan M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998;339(1):12-20.
693. Steingart RM, Packer M, Hamm P, et al. Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med 1991;325(4):226-30.
694. Stephens MB. Is electron-beam computed tomography (EBCT) a reliable tool for predicting coronary outcomes in an asymptomatic population? J Fam Pract 2000;49(8):688.
695. Sterling TD, Rosenbaum WL, Weinkam JJ. Risk attribution and tobacco-related deaths. Am J Epidemiol 1993;138(2):128-39.
696. Stern MP, Haffner SM. Body fat dis tribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986;6(2):123-30.
697. Stokes J, 3rd, Kannel WB, Wolf PA, et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study--30 years of follow-up. Hypertension 1989;13(5 Suppl):I13-8.
698. Stone GW, Grines CL, Browne KF, et al. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 1995;75(15):987-92.
699. Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. Jama 1996;275(14):1104-12.

700. Strandberg TE, Pitkanen A, Larjo P, et al. Attitude changes of general practitioners towards lowering LDL cholesterol. J Cardiovasc Risk 1998;5(1):43-6.
701. Strauss R, Pfeifer C, Muhlberger V, et al. Effects of morbidity, age, gender and region on percutaneous transluminal coronary angioplasty (PTCA) utilisation. Public Health 1999;113(2):79-87.
702. Stringer KA. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Ann Pharmacother 1999;33(6):712-22.
703. Sudano JJ, Jr., Baker DW. Antihypertensive medication use in Hispanic adults: a comparison with black adults and white adults. Med Care 2001;39(6):575-87.
704. Sullivan AK, Holdright DR, Wright CA, et al. Chest pain in women: clinical, investigative, and prognostic features. Bmj 1994;308(6933):883-6.
705. Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90(2):1056-69.
706. Swahn E. The care of patients with ischaemic heart disease from a gender perspective. Eur Heart J 1998;19(12):1758-65.
707. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990;322(23):1635-41.
708. Taggart DP. Angioplasty versus bypass surgery. Lancet 1996;347(8996):271-2; discussion 272-3.
709. Taillefer R, DePuey EG, Udelson JE, et al. Comparative diagnostic accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol 1997;29(1):69-77.
710. Tavel ME. Specificity of electrocardiographic stress test in women versus men. Am J Cardiol 1992;70(4):545-7.
711. Tchernof A, Despres JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 2000;32(11-12):526-36.
712. Thadani U. Oral nitrates: more than symptomatic therapy in coronary artery disease? Cardiovasc Drugs Ther 1999;11(Suppl 1):213-8.
713. Thijs L, Fagard R, Lijnen P, et al. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992;10(10):1103-9.
714. Thompson D, Edelsberg J, Colditz GA, et al. Lifetime health and economic consequences of obesity. Arch Intern Med 1999;159(18):2177-83.
715. Tice JA, Ross E, Coxson PG, et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. Jama 2001;286(8):936-43.
716. Tijssen JG. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. Neurology 1998;51(3 Suppl 3):S15-6.
717. Tisdale JE. Antiplatelet therapy in coronary artery disease: review and update of efficacy studies. Am J Health Syst Pharm 1998;55(19 Suppl 1):S8-16.
718. Tobin JN, Wassertheil-Smoller S, Wexler JP, et al. Sex bias in considering coronary bypass surgery. Ann Intern Med 1987;107(1):19-25.
719. Tofler GH, Stone PH, Muller JE, et al. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol 1987;9(3):473-82.
720. Toiber F, Murthy VS. Prescribing and usage patterns of two antihypertensive agents: a comparison of terazosin and enalapril. Hosp Formul 1991;26(10):811-3, 817-8.
721. Topol EJ. Coronary angioplasty for acute myocardial infarction. Ann Intern Med 1988;109(12):970-80.
722. Topol EJ. How should intravenous thrombolytic agents for acute myocardial infarction be selected? Cardiovasc Clin 1990;21(1):57-75; discussion 76-8.
723. Topol EJ. Treatment of acute myocardial infarction: in which patients should primary percutaneous transluminal coronary angioplasty be preferred to thrombolysis? Cardiologia 1996;41(9):843-7.
724. Topol EJ, Holmes DR, Rogers WJ. Coronary angiography after thrombolytic therapy for acute myocardial infarction. Ann Intern Med 1991;114(10):877-85.
725. Tsang TS, Barnes ME, Gersh BJ, et al. Risks of coronary heart disease in women: current understanding and evolving concepts. Mayo Clin Proc 2000;75(12):1289-303.

726. Tsuyuki RT, Teo KK, Ikuta RM, et al. Mortality risk and patterns of practice in 2,070 patients with acute myocardial infarction, 1987-92. Relative importance of age, sex, and medical therapy. Chest 1994;105(6):1687-92.
727. Tyroler HA. Serum lipoproteins as risk factors: recent epidemiologic studies in individuals with and without prevalent cardiovascular disease. Eur Heart J 1990;11(Suppl H):21-5.
728. Vaccarino V, Horwitz RI, Meehan TP, et al. Sex differences in mortality after myocardial infarction: evidence for a sex-age interaction. Arch Intern Med 1998;158(18):2054-62.
729. Vaccarino V, Krumholz HM, Berkman LF, et al. Sex differences in mortality after myocardial infarction. Is there evidence for an increased risk for women? Circulation 1995;91(6):1861-71.
730. Vaccarino V, Krumholz HM, Yarzebski J, et al. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med 2001;134(3):173-81.
731. Vaccarino V, Parsons L, Every NR, et al. Impact of history of diabetes mellitus on hospital mortality in men and women with first acute myocardial infarction. The National Registry of Myocardial Infarction 2 Participants. Am J Cardiol 2000;85(12):1486-9; A7.
732. Vaitkus PT. Percutaneous transluminal coronary angioplasty versus thrombolysis in acute myocardial infarction: a meta-analysis. Clin Cardiol 1995;18(1):35-8.
733. van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol 1998;32(Suppl 1):S31-5.
734. Van de Werf F. Implications of the GUSTO trial for thrombolytic therapy. Drugs 1996;52(3):307-12.
735. Van de Werf F, Topol EJ, Lee KL, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Jama 1995;273(20):1586-91.
736. van der Schouw YT, van der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347(9003):714-8.
737. van der Weijden T, Knottnerus JA, Ament AJ, et al. Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence. J Epidemiol Community Health 1998;52(9):586-94.
738. Van Train KF, Maddahi J, Berman DS, et al. Quantitative analysis of tomographic stress thallium-201 myocardial scintigrams: a multicenter trial. J Nucl Med 1990;31(7):1168-79.
739. Vidt DG, Pohl MA. Aggressive blood pressure lowering is safe, but benefit is still hard to prove. Cleve Clin J Med 1999;66(2):105-11.
740. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. Jama 1999;281(15):1407-14.
741. Wallenius S, Peura S, Klaukka T, et al. Who is using antihypertensive drugs? A prescription analysis from Finland. Scand J Prim Health Care 1996;14(1):54-61.
742. Walsh CR, Lloyd-Jones DM, Camargo CA, Jr., et al. Clinical trials of unfractionated heparin and low-molecular-weight heparin in addition to aspirin for the treatment of unstable angina pectoris: do the results apply to all patients? Am J Cardiol 2000;86(9):908-12.
743. Walsh JM, Grady D. Treatment of hyperlipidemia in women. Jama 1995;274(14):1152-8.
744. Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000;160(2):211-20.
745. Waters D. Calcium channel blockers: an evidence-based review. Can J Cardiol 1997;13(8):757-66.
746. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. Jama 1997;278(23):2093-8.
747. Weaver WD, White HD, Wilcox RG, et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Jama 1996;275(10):777-82.
748. Weber MM. Surgical management of unstable angina and symptomatic coronary artery disease. J Cardiovasc Nurs 2000;15(1):27-42.
749. Weintraub WS, Wenger NK, Jones EL, et al. Changing clinical characteristics of coronary surgery patients. Differences between men and women. Circulation 1993;88(5 Pt 2):II79-86.

750. Weintraub WS, Wenger NK, Kosinski AS, et al. Percutaneous transluminal coronary angioplasty in women compared with men. J Am Coll Cardiol 1994;24(1):81-90.
751. Welty FK, Mittleman MA, Healy RW, et al. Similar results of percutaneous transluminal coronary angioplasty for women and men with postmyocardial infarction ischemia. J Am Coll Cardiol 1994;23(1):35-9.
752. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993;329(4):247-56.
753. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 1996;94(5):1175-92.
754. White AD, Rosamond WD, Chambless LE, et al. Sex and race differences in short-term prognosis after acute coronary heart disease events: the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 1999;138(3 Pt 1):540-8.
755. White CW. Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials. Am J Med 1998;105(1A):63S-68S.
756. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation 1996;94(8):1826-33.
757. Wikstrand J, Berglund G, Tuomilehto J. Beta-blockade in the primary prevention of coronary heart disease in hypertensive patients. Review of present evidence. Circulation 1991;84(6 Suppl):VI93-100.
758. Wilkinson P, Laji K, Ranjadayalan K, et al. Acute myocardial infarction in women: survival analysis in first six months. Bmj 1994;309(6954):566-9.
759. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317(21):1303-9.
760. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. Jama 1995;273(6):461-5.
761. Williams JE, Massing M, Rosamond WD, et al. Racial disparities in CHD mortality from 1968-1992 in the state economic areas surrounding the ARIC study communities. Atherosclerosis Risk in Communities. Ann Epidemiol 1999;9(8):472-80.
762. Williams PT. Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc 2001;33(5):754-61.
763. Williams SV, Fihn SD, Gibbons RJ. Guidelines for the management of patients with chronic stable angina: diagnosis and risk stratification. Ann Intern Med 2001;135(7):530-47.
764. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000;160(7):939-44.
765. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8(6):737-41.
766. Wong JB, Sonnenberg FA, Salem DN, et al. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990;113(11):852-71.
767. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991;115(9):687-93.
768. Woodfield SL, Lundergan CF, Reiner JS, et al. Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol 1997;29(1):35-42.
769. Wooster MB, Luzier AB. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction. Ann Pharmacother 1999;33(3):318-24.
770. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
771. Wu AH, Lane PL. Metaanalysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases. Clin Chem 1995;41(8 Pt 2):1228-33.
772. Yapp CK, Taylor LS, Ow CY, et al. Hypertension management: a comparison of urban versus rural general practitioners in Western Australia. Clin Exp Pharmacol Physiol 1995;22(6-7):447-9.
773. Yarzebski J, Col N, Pagley P, et al. Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1996;131(1):43-50.

774. Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and nondiabetic subjects. Diabet Med 1999;16(3):219-27.
775. Yusuf S. Interventions that potentially limit myocardial infarct size: overview of clinical trials. Am J Cardiol 1987;60(2):11A-17A.
776. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation 1995;92(5):1079-82.
777. Yusuf S, Anand S, Avezum A, Jr., et al. Treatment for acute myocardial infarction. Overview of randomized clinical trials. Eur Heart J 1996;17(Suppl F):16-29.
778. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6(7):556-85.
779. Yusuf S, Pogue J. Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction. Jama 1997;278(23):2110-1.
780. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-53.
781. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502.
782. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344(8922):563-70.
783. Zahn R, Schiele R, Schneider S, et al. Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis. Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR). J Am Coll Cardiol 2000;36(7):2064-71.
784. Zarembski DG, Nolan PE, Jr., Slack MK, et al. Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 1996;77(14):1247-50.
785. Zusman RM, Chesebro JH, Comerota A, et al. Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection. Clin Cardiol 1999;22(9):559-73.